®ADMEcell Enters into an Agreement To Exclusively Distribute RD-Biotech's FastELYSA® product line throughout North America 1/20/2011 Emeryville, Calif., January 20, 2011 ADMEcell, Inc. today announced that it has entered into an exclusive agreement with RD-Biotech, Besancon, France, to distribute the FastELYSA® product line in the North American market. The FastELYSA® products are a new, innovative Ready-to-Use ELISA kits designed to reduce the time and cost of quantification and isotyping of immunoglobulins in antibody drug development process. The FastELYSA® product line provides an off-the-shelf and user-friendly stand alone kit as well as a solution for high-throughput automated procedures. RD-Biotech (www.rd-biotech.com) is a leader in providing products, services and reagents for the biotech industry, including Ready-to-Use assay kits. RD-Biotech's business model allows it to achieve substantial reductions in costs, risks and the development time. Their most successful product to date is the FastELYSA® product line, which provides a simple and rapid method for quantification of immunoglobulins concentration in various species as well as isoptyping of the mouse immunoglobulins. RD-Biotech operates throughout five divisions: molecular biology, which concentrates its activity on development through to clinical concept testing of innovative pharmaceuticals in search for new applications of known molecules; Analytical Testing, which involves sample preparation, analytical service and analytical method development from research through product prototypes; cell culture development and production (primary cells or cell lines); immunology with a focus on in-vitro development and production of monoclonal antibodies; and Ready-to- Use ELISA products from concept to manufacturing. Licensing and Distribution Opportunities: ADMEcell, a Bay Area based biotechnology company is currently considering the licensing and/or distribution of unique, state-of-the-art Ready-to-Use kits that have important applications in the drug discovery process. Please contact ADMEcell (info@admecell.com) in confidence if you have a unique, compelling Ready-to-Use kit that is relevant to the biotechnology and life science marketplace, particularly to ADME-toxicology. link Press Release / Story ADMEcell Enters into an Agreement to Exclusively Distribute RD-Biotech products Throughout North America. www.admecell.comSandy Koshkin Email sandy@admecell.com

Emeryville, CA, July 15, 2009 — ADMEcell, Inc. today announced that it has entered into an exclusive agreement with Sovicell, Leipzig, Germany, to distribute the TRANSIL® product line for the North American market. The TRANSIL Membrane Permeability Kits and TRANSIL Protein Binding Kits are ready- to-use, innovative and state-of-the-art enabling tools to obtain rapid, accurate and reproducible pharmacokinetic data for drug candidates. The TRANSIL products are supplied in 96 well plates, ready-to-use, and no reagent preparation is required by our customers. They are ideal for automation.

About SovicellSovicell, located in Leipzig, Germany, is a leader in providing trusted state-of-the-art ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicology) products and services that enable customers to obtain, rapid, accurate and reproducible pharmacokinetic data about their drug candidates or other test substances.

The TRANSIL technology platform, based on a novel micro beads system, underpins its reliable membrane permeability and protein binding assays. While the range of SOVICYTE cell lines, with their in vivo-relevant metabolic properties, form the core of our drug metabolism and cytotoxicity assays.

About ADMEcellADMEcell, Inc. is an on-demand supplier of ready-to-use cell-based and other assay kits servicing the biotech and life sciences industries. Located in Emeryville, California, the company manufactures and distributes innovative and leading edge products through licensing and distribution agreements. ADMEcell’s product offerings enable rapid, sophisticated ready-to-use assays designed for in vitro therapeutic modeling and re-profiling. The common theme among the selected technologies is their leading edge nature and prominence within a chosen market. ADMEcell

Licensing and Distribution Opportunties

ADMEcell is currently considering the licensing and/or distribution of unique, state-of-the-art ready to use cell-based and other assays that have important applications in the drug discovery process. We are located in the San Francisco bay area and are partnered closely with a cell culture manufacturer to produce products under GMP. Please contact ADMEcell in confidence if you have a unique, compelling cell-based assay that is relevant to the biotechnology and life science marketplace, particularly to ADME-toxicology. www.admecell.com

Emeryville, CA, February 20, 2009 — ADMEcell, Inc. today announced that it has entered into an exclusive agreement with Advancell, Barcelona, Spain, to manufacture and distribute the CacoReady™ System for the North American market. The CacoReady™ System is a new, innovative tool designed to optimize the time and costs of evaluating the intestinal absorption of compounds. The kit has been designed to provide an off-the-shelf user-friendly standalone kit as well as a solution suitable for high-throughput automated procedures. It provides users with the differentiated Caco-2 barrier (21-day system), plated on 24- or 96-Transwell plates.

“This kit with differentiated Caco-2 cell barriers (shipped at day 13 of differentiation) is an innovation that is being offered in North America for the first time,” says Sandy Koshkin, President of ADMEcell. “Our customers gain considerable savings of both cost and time.” The CacoReady product is shipped in proprietary shipping media at room temperature, and arrives ready for immediate use.

About AdvancellAdvancell is a leader in nanomedicine and services and reagents in both ADME/Tox and Skin Biology areas, including cell-based assays. Advancell’s business model allows it to achieve substantial reductions in costs, risks and the development time of a drug. Their most successful product to date is the CacoReady™ System, which measures intestinal absorption of newly discovered drugs. ADVANCELL operates throughout three divisions: Advancell Therapeutics, which concentrates its activity in development, through to clinical concept testing of innovative pharmaceuticals in the search for new applications for known molecules; Advancell Alternative Testing, which uses in-vitro methods to predict cell efficiency, security, and the mechanism of molecule development, and Advancell Nanosystems, which uses nano-medicine to treat and prevent illnesses. The company is headquartered in Barcelona and has three different research centres in Spain. www.advancell.net

About ADMEcellADMEcell, Inc. is an on-demand supplier of cell-based assay kits servicing the biotech and life sciences industries. Located in Emeryville, California, the company manufactures and distributes innovative and leading edge products through licensing and distribution agreements. ADMEcell's product offerings enable rapid, sophisticated cell-based assays designed for in vitro therapeutic modeling and re-profiling. The common theme among the selected technologies is their leading edge nature and prominence within a chosen market. www.admecell.com

Licensing and Distribution Opportunties

ADMEcell is currently considering the licensing and/or distribution of unique, state-of-the-art cell-based assays that have important applications in the drug discovery process. We are located in the San Francisco bay area and are partnered closely with a cell culture manufacturer to produce products under GMP. Please contact ADMEcell in confidence if you have a unique, compelling cell-based assay that is relevant to the biotechnology and life science marketplace, particularly to ADME-toxicology. www.admecell.com